JPH07505646A - 神経伝達速度の減損を伴う障害,特に糖尿病性ニューロパシーに対するアンギオテンシンiiアンタゴニスト - Google Patents
神経伝達速度の減損を伴う障害,特に糖尿病性ニューロパシーに対するアンギオテンシンiiアンタゴニストInfo
- Publication number
- JPH07505646A JPH07505646A JP5518094A JP51809493A JPH07505646A JP H07505646 A JPH07505646 A JP H07505646A JP 5518094 A JP5518094 A JP 5518094A JP 51809493 A JP51809493 A JP 51809493A JP H07505646 A JPH07505646 A JP H07505646A
- Authority
- JP
- Japan
- Prior art keywords
- biphenyl
- pharmaceutically acceptable
- methyl
- tetrazol
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (12)
- 1.温血動物における神経伝達速度の減損を伴う疾患状態の進行を治療又は予防 する方法であって、かかる治療を必要とする前記動物に治療有効量のアンギオテ ンシンIIアンタゴニスト又は薬学的に許容できるその塩を投与することを含む 方法。
- 2.温血動物における神経伝達速度の減損を回復する方法であって、かかる治療 を必要とする前記動物に治療有効量のアンギオテンシンIIアンタゴニスト活性 を有する化合物又は薬学的に許容できるその塩を投与することを含む方法。
- 3.温血動物における糖尿病性ニューロパシーを治療又は予防する方法であって 、かかる治療を必要とする前記動物に治療有効量のアンギオテンシンIIアンタ ゴニスト活性を有する化合物又は薬学的に許容できるその塩を投与することを含 む方法。
- 4.AIIアンタゴニストが以下から選ばれる、請求項1、2又は3で特許請求 した方法。 (a)2−ブチル−4−クロロ−5−ヒドロキシメチル−1−〔(2′−(IH −テトラゾール−5−イル)ビフェニル−4−イル)メチル〕イミダゾ−ル; (b)2−ブチル−3−(2′−(IH−1,2,3,4−テトラゾール−5− イル)ビフェニル−4−イル)メチル−3H−イミダゾ〔4.5−b〕ビリジン :(c)5.7−ジメチル−2−エチル−3−(2′−(テトラゾール−5−イ ル)ビフェニル−4−イル)メチル−3H−イミダゾ〔4,5−b〕ビリジン; (d)1−1〔3−ブロモ−2−〔2−(IH−テトラゾール−5−イル)フェ ニル〕−5−ベンゾフラニル]メチル−2−ブチル−4−クロロ−IH−イミダ ゾール−5−カルボン酸; (e)2−エチル−4−〔(2′−(IH−1,2,3,4−テトラゾール−5 −イル)ビフェニル−4−イル)メトキシ〕キノリン;(f)2−エチル−5, 6,7,8−テトラハイドロ−4−〔(2′−(IH−1,2,3,4−テトラ ゾール−5−イル)ビフェニル−4−イル)メトキシ〕キノリン; (g)5.7−ジェチル−1−〔(2′−(IH−テトラゾール−5−イル)ビ フェニル−4−イル)メチル]−1.6−ナフチリジン−2(IH)−オン;及 び (h)5.7−ジエチル−1−〔(2′−(IH−テトラゾール−5−イル)ビ フェニル−4−イル)メチル〕−1,2,3,4,テトラハイドロ−1,6−ナ フチリジン−2−オン; 又は薬学的に許容できるその塩。
- 5.AIIアンタゴニストが2−エチル−4−〔(2′−(IH−1,2,3, 4−テトラゾール−5−イル)ビフェニル−4−イル)メトキシ〕キノリン又は 薬学的に許容できるその塩である、請求項1、2又は3で特許請求した方法。
- 6.神経伝達速度の減損を伴う疾患状態の進行の治療又は予防に用いる医薬品の 製造のためのアンギオテンシンIIアンタゴニスト又は薬学的に許容できるその 塩の使用。
- 7.神経伝達速度の減損の回復に用いる医薬品の製造のためのAIIアンタゴニ スト活性を有する化合物又は薬学的に許容できるその塩の使用。
- 8.糖尿病性ニューロパシーの治療又は予防に用いる医薬品の製造のためのAI Iアンクゴエスト活性を有する化合物又は薬学的に許容できるその塩の使用。
- 9.AIIアンタゴニストが以下から選ばれる、請求項6、7又は8で特許請求 したAIIアンタゴニスト活性を有する化合物の使用。 (a)2−ブチル−4−クロロ−5−ヒドロキシメチル−1−〔(2′−(IH −テトラゾール−5−イル)ビフェニル−4−イル)メチル〕イミダゾール; (b)2−ブチル−3−(2′−(IH−1,2.3.4−テトラゾール−5− イル)ビフエニル−4−イル)メチル−3H−イミダゾ〔4.5−b〕ビリジン ;(c)5,7ジメチル−2−エチル−3−(2′−(テトラゾール−5−イル )ビフェニル−4−イル)メチル−3H−イミダゾ〔4.5−b〕ビリジン;( d)1−〔〔3−ブロモ−2−〔2−(IH−テトラゾール−5−イル)フェニ ル〕−5−ベンゾフラニル〕メチル−2−ブチル−4−クロロ−IH−イミダゾ ール−5−カルボン酸; (e)2−エチル−4−〔(2′−(IH−1.2.3.4−テトラゾール−5 −イル)ビフェニル−4−イル)メトキシ〕キノリン;(f)2−エチル−5, 6,7,8−テトラハイドロ−4−〔(2′−(IH−1,2,3,4−テトラ ゾール−5−イル)ビフェニル−4−イル)メトキシ〕キノリ(g)5,7−ジ エチル−1−〔(2′−(IH−テトラゾール−5−イル)ビフュニル−4−イ ル)メチル]−1.6−ナフチリジン−2(IH)−オン;及び (h)5.7−ジエチル−1−〔(2′−(IH−テトラソ/−ル−5−イル) ビフェニル−4−イル)メチル]−1,2,3,4−テトラハイドロ−1,6− ナフチリジン−2−オン; 及び薬学的に許容できるそれらの塩。
- 10.AIIアンタゴニストが2−エチル−4−〔(2′−(IH−1,2,3 ,4−テトラソール−5−イル)ビフェニル−4−イル)メトキシ〕キノリン又 は薬学的に許容できるその塩である、請求項6、7又は8で特許請求したAII アンタゴニスト活性を有する化合物の使用。
- 11.神経伝達速度の減損を伴う疾患状態の進行の治療又は予防に必要な1又は 2以上の薬品と共にアンギオテンシンIIアンタゴニスト又は薬学的に許容でき るその塩を含む医薬組成物。
- 12.薬品がアルドースリダク夕ーゼ阻害剤又は血糖低下剤から選ばれる、請求 項IIで特許請求した医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9208116.5 | 1992-04-13 | ||
GB929208116A GB9208116D0 (en) | 1992-04-13 | 1992-04-13 | Therapeutic agents |
GB929211289A GB9211289D0 (en) | 1992-05-28 | 1992-05-28 | Heterocyclic therapeutic agents |
GB9211289.5 | 1992-05-28 | ||
PCT/GB1993/000732 WO1993020816A1 (en) | 1992-04-13 | 1993-04-07 | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07505646A true JPH07505646A (ja) | 1995-06-22 |
Family
ID=26300705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5518094A Pending JPH07505646A (ja) | 1992-04-13 | 1993-04-07 | 神経伝達速度の減損を伴う障害,特に糖尿病性ニューロパシーに対するアンギオテンシンiiアンタゴニスト |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP0636027B1 (ja) |
JP (1) | JPH07505646A (ja) |
KR (1) | KR100292396B1 (ja) |
AT (1) | ATE181830T1 (ja) |
AU (1) | AU675935B2 (ja) |
CA (1) | CA2132544C (ja) |
DE (1) | DE69325574T2 (ja) |
DK (1) | DK0636027T3 (ja) |
ES (1) | ES2135472T3 (ja) |
GR (1) | GR3031261T3 (ja) |
HU (1) | HUT71331A (ja) |
NO (1) | NO313935B1 (ja) |
NZ (1) | NZ251741A (ja) |
WO (1) | WO1993020816A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071931A (en) * | 1995-10-06 | 2000-06-06 | Novartis Ag | AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
ES2189940T3 (es) | 1996-02-29 | 2003-07-16 | Novartis Ag | Antagonista de receptor at1 para la estimulacion de la apoptosis. |
RU2188013C2 (ru) * | 1996-04-05 | 2002-08-27 | Такеда Кемикал Индастриз, Лтд. | Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность |
US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
NZ587909A (en) | 1998-12-23 | 2012-05-25 | Novartis Ag | Process of making a compressed tablets containing valsartan and microcrystalline cellulose |
CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
EP2650011A1 (en) | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis |
US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
AU2007229322B2 (en) | 2006-03-20 | 2012-04-05 | Novartis Ag | Method of treatment or prophylaxis inflammatory pain |
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
US9095587B2 (en) * | 2010-01-19 | 2015-08-04 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
EA202090205A1 (ru) | 2017-07-07 | 2020-06-02 | Бёрингер Ингельхайм Ветмедика Гмбх | Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL286445A1 (en) * | 1989-08-11 | 1991-04-22 | Ici Plc | Method of obtaining novel quinoline derivatives |
GB8927277D0 (en) * | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
US5140037A (en) * | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
GB9027210D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
GB9027211D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
AU1625192A (en) * | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
DE59208448D1 (de) * | 1991-08-15 | 1997-06-12 | Ciba Geigy Ag | N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten |
-
1993
- 1993-04-07 NZ NZ251741A patent/NZ251741A/en not_active IP Right Cessation
- 1993-04-07 HU HU9402932A patent/HUT71331A/hu not_active Application Discontinuation
- 1993-04-07 DE DE69325574T patent/DE69325574T2/de not_active Expired - Fee Related
- 1993-04-07 JP JP5518094A patent/JPH07505646A/ja active Pending
- 1993-04-07 EP EP93909041A patent/EP0636027B1/en not_active Expired - Lifetime
- 1993-04-07 EP EP98108683A patent/EP0872235A1/en not_active Withdrawn
- 1993-04-07 AT AT93909041T patent/ATE181830T1/de not_active IP Right Cessation
- 1993-04-07 AU AU39589/93A patent/AU675935B2/en not_active Ceased
- 1993-04-07 DK DK93909041T patent/DK0636027T3/da active
- 1993-04-07 CA CA002132544A patent/CA2132544C/en not_active Expired - Fee Related
- 1993-04-07 ES ES93909041T patent/ES2135472T3/es not_active Expired - Lifetime
- 1993-04-07 WO PCT/GB1993/000732 patent/WO1993020816A1/en active IP Right Grant
-
1994
- 1994-10-11 KR KR19940703608A patent/KR100292396B1/ko not_active IP Right Cessation
- 1994-10-12 NO NO19943846A patent/NO313935B1/no not_active IP Right Cessation
-
1999
- 1999-09-20 GR GR990402358T patent/GR3031261T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU3958993A (en) | 1993-11-18 |
KR100292396B1 (ja) | 2001-09-17 |
WO1993020816A1 (en) | 1993-10-28 |
NO943846L (no) | 1994-10-12 |
EP0636027B1 (en) | 1999-07-07 |
ATE181830T1 (de) | 1999-07-15 |
NO943846D0 (no) | 1994-10-12 |
NO313935B1 (no) | 2002-12-30 |
EP0636027A1 (en) | 1995-02-01 |
DE69325574D1 (de) | 1999-08-12 |
CA2132544C (en) | 2005-10-18 |
CA2132544A1 (en) | 1993-10-28 |
AU675935B2 (en) | 1997-02-27 |
ES2135472T3 (es) | 1999-11-01 |
DK0636027T3 (da) | 2000-01-31 |
HU9402932D0 (en) | 1995-02-28 |
DE69325574T2 (de) | 2000-03-16 |
NZ251741A (en) | 1997-06-24 |
EP0872235A1 (en) | 1998-10-21 |
GR3031261T3 (en) | 1999-12-31 |
HUT71331A (en) | 1995-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2336833C (en) | Remedy with antidepressant effects | |
JPH07505646A (ja) | 神経伝達速度の減損を伴う障害,特に糖尿病性ニューロパシーに対するアンギオテンシンiiアンタゴニスト | |
JP6891385B2 (ja) | トラジピタントによる治療方法 | |
AU2019216742B2 (en) | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction | |
JP2009517393A (ja) | 不安症の治療方法 | |
JPH06510544A (ja) | 尿酸排泄促進剤およびeaa拮抗剤の組合せのための医薬組成物 | |
JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用 | |
EP2343976A1 (en) | Methods of using sustained release aminopyridine compositions | |
JP2003176240A (ja) | ニコチン性アセチルコリン受容体作用薬により関節の潤滑を高める方法 | |
JP2003520237A (ja) | 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤 | |
JP2002509540A (ja) | アルドースレダクターゼ阻害剤およびace阻害剤を含有する医薬組成物 | |
EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
RU2633637C2 (ru) | Паралитический яд моллюсков | |
US6448280B1 (en) | Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
KR20060020664A (ko) | 과체중 또는 과체중 경향을 가진 환자에서 정신 분열증의치료를 위한 아세나핀 | |
NL8002041A (nl) | Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel. | |
KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
EP3570841A1 (en) | PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE | |
JP2003530350A (ja) | 外傷性脳損傷及びその他のニューロン障害治療用医薬 | |
Magat et al. | Oral spasmolytics | |
JP5127092B2 (ja) | 小脳機能障害を予防および治療するための2−アミノ−6−トリフルオロメトキシ−ベンゾチアゾールの使用 | |
JP2004002353A (ja) | 医薬組成物 | |
WO1999007356A1 (en) | Nicotine antagonists for neuropsychiatric disorders | |
JP3381198B2 (ja) | 1,4−ジヒドロピリジンの糖尿病における使用 | |
JP2004175786A (ja) | I型アレルギー疾患治療用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040609 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040909 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050719 |